Tarsus Pharmaceuticals entered into an Agreement and Plan of Merger to acquire iRenix Medical. The deal closed July 6, 2026, for $37.5 million in cash, subject to adjustments, plus 607,093 Tarsus common shares. iRenix equityholders may receive up to $490 million in regulatory and commercial milestones and low-to-mid single-digit revenue sharing on certain future net sales. An escrow was established to secure indemnification and purchase price adjustments.
Agreement details:
- Agreement type: Agreement and Plan of Merger
- Counterparty: iRenix Medical
- Signed / Effective: Jul 06 2026 / same
- Reason: Expand pipeline and future revenue opportunities
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.